Prevalence of Transthyretin Amyloidosis in Patients with Heart Failure and No Left Ventricular Hypertrophy

Abstract

In a cohort of patients with HFpEF without LVH, the prevalence of TTR cardiac amyloidosis was 5%. Early diagnosis of cardiac involvement in TTR amyloidosis (before manifest LVH) would seem recommendable because newly approved specific treatments can prevent additional deposition of amyloid material.